MacOrtho is excited to announce that the PARITY trial has just enrolled their 75th patient. Over a short period of time, the PARITY trial has not only proven feasibility of a Canadian multi-centre randomized trial in orthopaedic oncology but also successfully expanded internationally to the United States, Australia and Argentina. The definitive trial aims to include 600 patients.
The PARITY trial is investigating whether long duration post-operative prophylactic antibiotics decreases the rate of surgical site infections compared to standard shorter duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-centre randomized trials were possible in their specialty. The success of the PARITY has demonstrated that these types of study are, in fact, possible.